Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all: towards MRD for all

Roland P Kuiper, Patricia G Hoogeveen, Reno Bladergroen, Freerk van Dijk, Edwin Sonneveld, Frank N van Leeuwen, Judith Boer, Irina Sergeeva, Harma Feitsma, Monique L den Boer

Research output: Contribution to journalArticlepeer-review

Abstract

Minimal residual disease (MRD) diagnostics are implemented in most clinical protocols for patients with acute lymphoblastic leukaemia (ALL) and are mostly performed using rearranged immunoglobulin (IG) and/or T-cell receptor (TR) gene rearrangements as molecular polymerase chain reaction targets. Unfortunately, in 5-10% of patients no or no sensitive IG/TR targets are available, and patients therefore cannot be stratified appropriately. In the present study, we used fusion genes and genomic deletions as alternative MRD targets in these patients, which retrospectively revealed appropriate MDR stratification in 79% of patients with no (sensitive) IG/TR target, and a different risk group stratification in more than half of the cases.

Original languageEnglish
Pages (from-to)888-892
Number of pages5
JournalBritish journal of haematology
Volume194
Issue number5
DOIs
Publication statusPublished - Sep 2021

Keywords

  • Child
  • Gene Deletion
  • Humans
  • Neoplasm, Residual/diagnosis
  • Oncogene Fusion
  • Polymerase Chain Reaction
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis

Fingerprint

Dive into the research topics of 'Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all: towards MRD for all'. Together they form a unique fingerprint.

Cite this